INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today ...

Inovalis Real Estate Investment Trust (the “REIT”) (TSX: INO.UN) today announced the signing of an exchange contract for the sale of the Sablière prop ...

Shares of Inovio Pharmaceuticals Inc. INO slipped 2.91% to $4.01 Tuesday, on what proved to be an all-around favorable ...

Inovio Pharmaceuticals (NASDAQ:INO – Get Free Report) had its target price reduced by HC Wainwright from $12.00 to $5.00 in a ...

Inovio Pharmaceuticals (NASDAQ:INO – Free Report) had its price objective cut by Royal Bank of Canada from $7.00 to $6.00 in ...

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the ...

H.C. Wainwright analyst Ram Selvaraju has reiterated their neutral stance on INO stock, giving a Hold rating on November 14.Don't Miss our ...

Inovio Pharmaceuticals (INO – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Roy ...

New immunology data for INO-3107 supporting proposed mechanism of action presented at several recent conferences Data showed ability of INO-3107 to induce an ...

As RBC Capital continues to monitor Inovio's INO-3107 progress, the competitive environment, and pipeline developments, the firm has revised its price target but remains cautious with its Sector ...